[HTML][HTML] The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes
Exposure histories to SARS-CoV-2 variants and vaccinations will shape the specificity of
antibody responses. To understand the specificity of Delta-elicited antibody immunity, we …
antibody responses. To understand the specificity of Delta-elicited antibody immunity, we …
[HTML][HTML] Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants
S Moriyama, Y Adachi, T Sato, K Tonouchi, L Sun… - Immunity, 2021 - cell.com
Antibody titers against SARS-CoV-2 slowly wane over time. Here, we examined how time
affects antibody potency. To assess the impact of antibody maturation on durable …
affects antibody potency. To assess the impact of antibody maturation on durable …
Improving the outcomes of immunocompromised patients with coronavirus disease 2019
G Haidar, JW Mellors - Clinical Infectious Diseases, 2021 - academic.oup.com
Recent case studies have highlighted the fact that certain immunocompromised individuals
are at risk for prolonged SARS-CoV-2 replication, intrahost viral evolution of multiply …
are at risk for prolonged SARS-CoV-2 replication, intrahost viral evolution of multiply …
[HTML][HTML] Impact of mAb-induced A475V substitution on viral fitness and antibody neutralization of SARS-CoV-2 omicron variants in the presence of monoclonal …
R Viriyakitkosol, A Wanitchang… - Frontiers in …, 2023 - frontiersin.org
The emergence and rapid evolution of SARS-CoV-2 variants have posed a major challenge
to the global efforts to control the COVID-19 pandemic. In this study, we investigated the …
to the global efforts to control the COVID-19 pandemic. In this study, we investigated the …
[HTML][HTML] Patient-derived SARS-CoV-2 mutations impact viral replication dynamics and infectivity in vitro and with clinical implications in vivo
H Yao, X Lu, Q Chen, K Xu, Y Chen, M Cheng, K Chen… - Cell discovery, 2020 - nature.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally
with more than 33 million patients diagnosed, taking more than a million lives. Abundant …
with more than 33 million patients diagnosed, taking more than a million lives. Abundant …
Effectiveness of casirivimab-imdevimab and sotrovimab during a SARS-CoV-2 Delta variant surge: a cohort study and randomized comparative effectiveness trial
DT Huang, EK McCreary, JR Bariola… - JAMA Network …, 2022 - jamanetwork.com
Importance The effectiveness of monoclonal antibodies (mAbs), casirivimab-imdevimab and
sotrovimab, is unknown in patients with mild to moderate COVID-19 caused by the SARS …
sotrovimab, is unknown in patients with mild to moderate COVID-19 caused by the SARS …
[HTML][HTML] SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis
Z Raglow, D Surie, JD Chappell, Y Zhu… - The Lancet …, 2024 - thelancet.com
Summary Background Prolonged SARS-CoV-2 infections in people who are
immunocompromised might predict or source the emergence of highly mutated variants. The …
immunocompromised might predict or source the emergence of highly mutated variants. The …
SARS-CoV-2 E484K mutation narrative review: epidemiology, immune escape, clinical implications, and future considerations
WT Yang, WH Huang, TL Liao, TH Hsiao… - Infection and Drug …, 2022 - Taylor & Francis
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly over the
world and claimed million lives. The virus evolves constantly, and a swarm of mutants is a …
world and claimed million lives. The virus evolves constantly, and a swarm of mutants is a …
[HTML][HTML] SARS-CoV-2 shedding and evolution in immunocompromised hosts during the Omicron period: a multicenter prospective analysis
Background: Prolonged SARS-CoV-2 infections in immunocompromised hosts may predict
or source the emergence of highly mutated variants. The types of immunosuppression …
or source the emergence of highly mutated variants. The types of immunosuppression …
[HTML][HTML] Monoclonal antibodies against SARS-CoV-2: current scenario and future perspectives
E Quiros-Roldan, S Amadasi, I Zanella, M Degli Antoni… - Pharmaceuticals, 2021 - mdpi.com
Monoclonal antibodies (mAbs) have been known since the 1970s. However, their
therapeutic potential in the medical field has recently emerged, with the advancement of …
therapeutic potential in the medical field has recently emerged, with the advancement of …